ZBTB39 Knockout HEK293 Cell Line
Cat.No.:
EDC08268
Species:
Human
Cell Name:
HEK293
Gene:
ZBTB39
Gene ID:
9880
Size:
1×10⁶cells
ZBTB39 Knockout Cell Line (HEK293) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDC08268 |
|---|---|
| Product Name | ZBTB39 Knockout Cell Line(HEK 293) |
| Cell Line | HEK293 |
| Cellosaurus ID | CVCL_0045 |
| Cell Line Synonyms | Hek293, HEK-293, HEK/293, (HEK)293, HEK 293, HEK,293, 293, 293 HEK, 293 Ad5, Graham 293, Graham-293, Human Embryonic Kidney 293 |
| Gene | ZBTB39 |
| NCBI Gene ID | |
| Gene Synonyms | ZNF922 |
| Summary |
Predicted to enable DNA-binding transcription repressor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in negative regulation of transcription by RNA polymerase II; regulation of cytokine production; and regulation of immune system process. Predicted to be located in nucleus. Predicted to be active in nucleoplasm. [provided by Alliance of Genome Resources, Jul 2025]
|
| Associated Diseases | Non-tumor |
| Morphology | Adherent |
| Passage Ratio | 1/5,2days |
| Complete Culture Medium | DMEM + 10% FBS |
| Freezing Medium | 95% Complete culture medium+ 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: HEK293 | STR Info (Cell bank) Cell Line: HEK293 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | X | ||
| CSF1P0 | 12 | 11 | 12 | |
| D2S1338 | 19 | 19 | ||
| D3S1358 | 15 | 17 | 15 | 17 |
| D5S818 | 8 | 8 | 9 | |
| D7S820 | 11 | 12 | 11 | 12 |
| D8S1179 | 12 | 14 | 12 | 14 |
| D13S317 | 12 | 14 | 12 | 14 |
| D16S539 | 9 | 13 | 9 | 13 |
| D18S51 | 17 | 18 | 17 | 18 |
| D19S433 | 15 | 18 | 15 | 18 |
| D21S11 | 28 | 30.2 | 28 | 30.2 |
| FGA | 23 | 23 | ||
| Penta D | 9 | 10 | 9 | 10 |
| Penta E | 7 | 15 | 7 | 15 |
| TH01 | 7 | 9.3 | 7 | 9.3 |
| TPOX | 11 | 11 | ||
| vWA | 16 | 19 | 16 | 19 |
| D6S1043 | 11 | 11 | ||
| D12S391 | 19 | 21 | 11 | 15 |
| D2S441 | 11 | 15 | 11 | 15 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Which is better for studying ZBTB39 function, ZBTB39 Knockout HEK293 Cell Line or ZBTB39 overexpression HEK293 Cell Line?
The choice depends on the experimental question, but for ZBTB39 — where prior functional characterization is limited — the framing of the question itself often needs to come first. The Knockout line is the appropriate tool for unbiased discovery: identifying transcripts and pathways affected by ZBTB39 loss without prior assumptions about its function. Overexpression is more useful once candidate regulatory activities have been proposed, allowing tests of sufficiency at specific loci.
For initial characterization of an understudied factor like ZBTB39, the EDITGENE Knockout line is the higher-value starting point — it generates the foundational data needed to guide subsequent overexpression experiments. Rescue with wild-type or BTB-domain mutant constructs then provides specificity controls and assigns function to structural domains.
What are the application scenarios for this model?
Primary applications:
• Discovery transcriptomics: RNA-seq to identify transcriptional changes associated with ZBTB39 loss, generating testable hypotheses about candidate downstream programs rather than validating pre-established pathways.
• Reporter assays: promoter and enhancer activity assays to probe regulatory function at specific genomic loci of interest.
• Protein interaction studies: co-immunoprecipitation or proximity labeling (BioID, TurboID) to identify BTB domain-dependent binding partners and place ZBTB39 within the broader ZBTB regulatory network.
• Rescue experiments: re-introduction of wild-type ZBTB39 or domain mutants to validate phenotypes and assign function to specific structural elements.
EDITGENE recommends this model as a starting platform for functional characterization of ZBTB39 in transcriptional regulatory biology.
Is this ZBTB39 Knockout HEK293 Cell Line compatible with overexpression rescue experiments?
Yes, and rescue experiments are particularly valuable for an understudied factor like ZBTB39 where specificity controls are essential:
• Construct design: use a codon-modified ZBTB39 sequence with a C-terminal tag (FLAG, HA). Avoid N-terminal tags near the BTB domain — this region mediates protein-protein interactions critical to ZBTB39 function.
• Domain mutant rescue: include both BTB domain mutants (disrupting co-repressor recruitment) and zinc finger DNA-binding mutants. For a factor with limited functional characterization, domain mutant rescues are often more informative than wild-type rescue alone — they help assign discovered phenotypes to specific protein activities.
• Expression level: titrate to approximate endogenous levels using inducible systems. For poorly characterized transcription factors, overexpression artifacts are a particularly serious concern because reference data on physiological function is limited.
• Functional readout: rescue should restore transcriptional changes identified in the discovery transcriptomics experiments. Discordance between wild-type and domain mutant rescue is often the most informative result for emerging factors.
HEK293 supports stable lentiviral integration with high transduction efficiency, making it well-suited for generating panels of rescue sublines.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
download